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p53 Aberrations do not predict individual response to
fludarabine in patients with B-cell chronic lymphocytic
leukaemia in advanced stages Rai III/IV
In recent years, genetic factors have been established as
important predictors of disease progression and survival in
patients with chronic lymphocytic leukaemia (CLL), and they
have implications for the risk-adapted clinical management of
CLL, particularly in younger patients (Dohner et al, 2000;
Krober et al, 2002; Lin et al, 2002; Stilgenbauer et al, 2002;
Shanafelt et al, 2004). These biologic markers are currently
being incorporated into clinical use as adjuncts to the classical
staging systems. Genetic aberrations that modify the expres-
sion of p53 (deletions and mutations) are independent poor
prognostic factors in CLL (Stilgenbauer et al, 2002). Growing
evidence has implicated aberrant promoter methylation in the
molecular pathogenesis of several human cancers (Esteller
et al, 2001). In vitro studies have demonstrated the expected
correlation between hypermethylation in the promoter region
of p53 and a decrease in the transcription of this gene (Mass &
Wang, 1997; Schroeder & Mass, 1997; Pogribny et al, 2000;
Pogribny & James, 2002; Agirre et al, 2003a), however, only a
few studies have been carried out in human malignancies. To
date, the role of aberrant promoter methylation in B-CLL has
not been investigated exhaustively, and widespread studies
have been mainly restricted to the p15 and p16 genes (Baur
et al, 1999; Rossi et al, 2004).
In many countries fludarabine is an approved first-line
therapy treatment for CLL, which achieves superior remission
rates when compared with traditional first-line therapies, such
as the chlorambucil and anthracyline-based regimens. The
drug is equally effective in early and advanced disease, and in
younger and older patients with CLL (Keating et al, 1998; Rai
et al, 2000; Leporrier et al, 2001; O’Brien et al, 2001; Lepor-
rier, 2004; Montserrat, 2004). The presence of either muta-
tions or deletions of the p53 gene has been reported to predict
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Summary
Abnormalities of p53 have been associated with short survival and non-
response to therapy in chronic lymphocytic leukaemia (CLL). We have
evaluated the rate of response to fludarabine as first-line therapy in 54
patients with advanced stage CLL, analysing the cytogenetic profile,
aberrations in p53, including the methylation status of its promoter, and
the immunoglobulin heavy-chain variable-region (IGVH) mutation status.
According to the advanced stage of the disease in this series, 75% of patients
presented genetic aberrations associated with poor prognosis: del(17p) and/
or del(11q), and no-mutated IGVH genes. Ten patients (18Æ5%) had
methylation in the promoter region of p53. Eighty-three per cent of patients
treated achieved a response, with a high rate of complete remission (47Æ6%).
Although we found a significant correlation between failures and the presence
of p53 aberrations (P ¼ 0Æ0065), either with methylation (P ¼ 0Æ018) or
deletion (P ¼ 0Æ015), 64% of the patients with aberrations in this gene
responded to treatment (11/17), suggesting that fludarabine induces high
remission rates, even in these patients. This is the first time that the
significance of p53 promoter methylation status is described in this
pathology, and our data support that this epigenetic phenomenon could be
involved in the pathogenesis and clinical evolution of CLL.
Keywords: chronic lymphocytic leukaemia, fludarabine, p53, methylation.
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non-response to therapy with purine analogues in two
independent series of CLL patients. el Rouby et al (1993)
analysed 53 B-CLL patients and found eight with p53
mutations. Only two patients (2/53) were treated with
fludarabine as first-line therapy, one had p53 mutations and
did not respond and the other, with no p53 mutations,
responded to treatment. In a retrospective study, Dohner et al
(1995) analysed the presence of 17p deletions in 90 patients
with CLL, and none of the 11 patients with del(17p)
responded to second line therapy with fludarabine. They
found that p53 gene deletion was the strongest prognostic
factor for survival after therapy. On the other hand, the
clinical trials using fludarabine as first-line therapy treatment
for CLL, do not include genetic analysis of p53. Thus, although
p53 mutations and/or deletions are widely associated with
resistance to chemotherapy and short survival in CLL, there
are few studies evaluating the association of p53 aberrations
and treatment with purine analogues, and none with fludara-
bine as first-line therapy. Indeed, in recent years, several
reports have described the modest contribution of p53 to the
nucleoside-induced killing of CLL cells (Pettitt et al, 1999a,
2001), supporting the use of nucleoside therapy in patients
with p53 defects. Therefore, the efficacy of fludarabine as first-
line therapy in patients with abnormalities on p53 is still
uncertain (Barnabas et al, 2001).
We have analysed the p53 methylation status, cytogenetic
aberrations with prognostic significance, including 17p dele-
tions, and the presence of somatic hypermutation of immu-
noglobulin heavy-chain variable-region gene (IGVH), in
patients with stage III/IV CLL, in order to assess the
association of these parameters with rates of response to
fludarabine as first-line therapy. We have confirmed in our
series the high efficacy of fludarabine in CLL, even in patients
with p53 aberrations. The presence of abnormalities on p53
was the only genetic factor related to non-response to
fludarabine, confirming the importance of this event in CLL,
but suggesting that p53 aberrations are not specifically
associated with non-response to purine analogue treatment.
Patients and methods
Patients
Patients were diagnosed with B-CLL based on standard
morphologic and immunophenotypic criteria, and classified
as high clinical risk category Rai stage III/IV. The median age
at diagnosis was 68 years; the male to female ratio was 1Æ3.
Table I summarizes the main clinical features of B-CLL
patients.
Treatment was initiated for progressive disease in 42 patients
with fludarabine as first-line therapy (25 mg/m2/d for 5 d
every 4 weeks). Criteria for progression and response were
established using the Revised 1996 National Cancer Institute
(NCI)-sponsored Working group Guidelines (Cheson et al,
1996) Samples were obtained after informed consent.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) studies were per-
formed using the probes LSI p53 (17p13), LSI D13S25 (13q14),
and CEP 12 (Vysis, Downers, Grove, IL, USA). In order to
detect aberrations of the ATM gene (11q22), we designed two
BAC clones that cover the gene: RPCI-11 241D13 and RPCI-11
415G10 (http://genome.ucsc.edu and http://www.ncbi.nlm.
nih.gov). FISH analysis was performed on fixed bone marrow
(BM) 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimula-
ted cultures as previously described (Odero et al, 2001).
Nucleic acid isolation
High molecular weight DNA and total RNA were extracted
from mononuclear cells isolated on a Ficoll gradient (Lympho-
prepTM, Nycomed, Oslo, Norway) from peripheral blood (PB)
and/or BM samples, using the QIamp DNA mini-kit and the
RNeasy mini-kit (Qiagen, Hilden, Germany) respectively.
Complementary DNA (cDNA) was synthesized from 1 lg of
total RNA using SuperScriptTM II Rnase H) RT (Invitrogen
Life Technologies, Paisley, UK) with random hexamers. DNA
from BAC and PAC clones was extracted using the QIAprep
Spin Miniprep kit (Qiagen).
Promoter methylation and mutational analysis of p53
A polymerase chain reaction (PCR) assay based on the inability
of some restriction enzymes (HpaII, EcoRII) to digest methy-
lated sequences, was used to analyse the methylation status of
the p53 promoter region as previously described (Agirre et al,
2003b). Positive results were considered after two independent
digestions and two independent PCR. These assays detect
methylation of the CpG dinucleotide located at position 883 of
the p53 promoter, and of the CC(A/T)GG sites located at
Table I. Clinical features of B-CLL patients at diagnosis.
Number of patients 54







WBC (·109/l) 18187 (4Æ0–89800)
Haemoglobin (g/dl) 13Æ8 (8Æ5–17)
Platelets (·109/l) 257Æ0 (49–144)
Number of patients treated
No 12
Yes 42
Number of cycles of therapy (mean/range) 6 (4–8)
Response
Complete remission 20/42 (47Æ7%)
Partial remission 15/42 (35Æ8%)
Failure 7/42 (16Æ6%)
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positions 756, 858 and 940 (Genbank accession no. X54156).
Mutations of p53 (5–8 exon) were studied with the SNPCapt-
ureTM p53 Mutation Screening Kit (Panomics, Bayshore Road
Redwood, CA, USA).
Mutation analysis of the IGVH genes
IGVH gene sequences were determined in patients’ cDNA as
previously described (Campbell et al, 1992). cDNA VH1 to
VH6 gene family-specific PCR amplifications were performed
using a mixture of 5¢oligonucleotides specific for each leader
sequence of the VH1 to VH6 IGVH gene families, together
with 3¢ primers complementary to the constant region (IgM or
IgG). PCR products were purified with the Jetquick PCR
purification spin kit (Genomed GmbH, Germany) or by gel
excision using the Jetquick gel extraction spin kit (Genomed
GmbH), and directly sequenced with the Abi-PrismTM
d-Rhodamine Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA), in an Abi PrimTM 377
DNA sequencer. Nucleotide sequences were aligned to publish
germ line IGVH genes using the dnaplot (http://
www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html) software and
the V-BASE data library (http://www.mrc-cpe.cam.ac.uk/).
Sequences with 2% or less deviation from any germline IGVH
sequence were considered unmutated.
Statistical analysis
Association was studied using contingence tables, followed by
Fisher exact test and mid-P. Mid-P is less conservative and
more powerful than the Fisher exact test, and has some
theoretical advantages (reviewed by Swinscow, 1997; Zojer
et al, 2000) The Statistical Package for the Social Sciences
(spss) macro was used to calculate a confidence interval for a
difference between two proportions a/m and b/n based on
unpaired data (independent groups), using an appropriate
method (Zhu et al, 2001).
Results
Clinical evaluation
Genetic analysis of samples from 54 patients with CLL in stages
III/IV at diagnosis was performed. Forty-two patients presen-
ted signs of progression and were treated. The response of
these 42 patients was evaluated according to the modified NCI
working group criteria for CLL (Cheson et al, 1996). Twenty
patients (47Æ6%) achieved complete remission (CR), 15
(35Æ7%) partial remission (PR), and 7 (16Æ7%) were failures.
Therefore, the overall response (OR) rate was 83Æ3%.
Fluorescence in situ hybridization
All 54 cases could be evaluated by interphase FISH cytogen-
etics; 44 (81%) had aberrations. Following the hierarchical
model of chromosomal abnormalities proposed by Dohner
et al (2000) 12 patients were classified in the del(17p) category,
13 del(11q), eight trisomy 12, nine normal, and 11 had
del(13q) as the sole abnormality (Table II). One patient could
not be included in any category because FISH analysis was
normal but the G-banding karyotype was abnormal. All
deletions were monoallelic, except for the 13q14 region: in
two patients (2/33, 6%) there were concomitant monoallelic
and biallelic deletions. In 22 patients (67%) del(13q) was
accompanied by other aberrations, the most frequent being
11q deletions (15 cases).
Methylation status of the p53 promoter
We detected methylation of either one CpG dinucleotide or
the three CC(A/T)GG motifs in the promoter region of p53 in
10 patients (10/54, 18Æ5%). Three cases showed methylation
in all cytosines analysed, three samples were only methylated
on the CC(A/T)GG motifs, and four samples were only
methylated in the CpG dinucleotide (Fig 1). Of the 10
patients, 3 (30%) also presented p53 deletion. The mutation
analysis of patients with p53 methylation or deletion showed
that only one deleted case also presented a nucleotide
substitution, located at position 179 in exon 5 of the p53
gene (Fig 2). Therefore, 35% of our patients presented p53
aberrations, and del(17p) and methylation of the p53
promoter, seemed to be independent factors (Table III).
When we analysed the concomitant presence of p53 aberra-
tions and other genetic events, we only found a significant
difference in the distribution of p53 aberrations in patients
with del(13q) (P ¼ 0Æ0331).
Mutational status of the IGVH genes
Forty-four patients could be analysed for the mutational
status of the IGVH gene. Somatic mutations of the IGVH
genes (<98% homology with the germ-line sequences) was
found in 42% patients (18/43, including six with 95–96Æ3%
homology), and 58% (25/43) presented >98% homology.
We only found a significant correlation between presence
of del(11q) and no mutated IGVH genes (P ¼ 0Æ0194)
(Table IV).
Table II. Incidence of chromosomal abnormalities detected by FISH







et al, 2000) (%)
11q deletion 18 (33) 13 (24)
12 trisomy 11 (20) 8 (15)
13q deletion 33 (61) 11 (20)
17p deletion 12 (22) 12 (22)
Normal FISH 10 (18) 9 (17)
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Correlation of genetic profiles with response rates
A significant correlation was found between non-response to
treatment and the presence of p53 aberrations (P ¼ 0Æ0065)
(Table III). We found a significant correlation in both
methylated (P ¼ 0Æ018) and deleted samples (P ¼ 0Æ015)
when compared with non-clinical response. Age less than
60 years was also associated with non-response (P ¼ 0Æ0090).
Discussion
We analysed the presence of genetic aberrations with prog-
nostic significance and their correlation with response rates to
fludarabine as first-line therapy, in a series of 54 patients with
CLL stages III/IV. Although we found a significant correlation
between failures and the presence of p53 aberrations
(P ¼ 0Æ0065), 64% of the patients with aberrations in this
gene responded to treatment, suggesting that fludarabine
induces high remission rates, even in these patients. This is the
first time that p53 aberrations, including the methylation status
of its promoter, have been evaluated as markers for response to
purine analogues in CLL.
We confirmed the high efficacy of fludarabine as first-line
therapy in CLL. Our series had an OR of 83Æ3%, with 47Æ6%
CR, which are similar to other extensive works in patients with
advanced stages of CLL (Rai et al, 2000; Leporrier et al, 2001),
however, neither of these works analysed the prognostic
impact of genetic markers.
As expected, our patients with advanced CLL had a high
percentage of genetic aberrations associated with poor prog-
nosis. FISH high-risk categories del(17p) and del(11q) were
present in 45% of the cases. Dohner et al (2000) found
deletions on 17p13 in 18% of patients in III/IV stages, a result
similar to the 22% reported in our series. This is consistent
with the fact that p53 deletion is usually considered as a marker
of progression, related with advanced stages of the disease.
Only 20% of our patients had del(13q) as a sole abnormality,
which is considered a good prognostic factor. Interestingly, we
found correlation between the presence of del(13q) and ATM
deletions (P ¼ 0Æ0138), according to the hypothesis that ATM
deletion is a secondary event in the clone with del(13q)
(Dohner et al, 2000; Cuneo et al, 2002; Krober et al, 2002).
In recent years, the presence of p53 aberrations has been
confirmed as an independent poor prognostic factor in CLL
(Gaidano et al, 1991; Fenaux et al, 1992; el Rouby et al, 1993;
Gaidano et al, 1994; Dohner et al, 1995) and, more recently,
several works have reported the prognostic and therapeutic
value of the mutational status of the IGVH genes in individual
patients (Damle et al, 1999; Hamblin et al, 1999). In fact, a
hierarchical risk profile based on a combination of high-risk
chromosomal abnormalities (17p- or 11q-) and IgVH muta-
tional status has been proposed (Krober et al, 2002). In
concordance with advanced stages of the disease, cases with no
hypermutation in the IGVH genes were frequently observed in
our series (58%), although we did not find the expected
association between this variable and p53 aberrations (Lin
et al, 2002; Oscier et al, 2002). As previously described, no
hypermutation (Krober et al, 2002) was related to ATM
deletions (P ¼ 0Æ0194).
We have confirmed for the first time in a homogeneous
series of advanced stage CLL patients that p53 aberrations are
associated with non-response to fludarabine (P ¼ 0Æ0065),
although our data indicate that this cannot be considered as an
individual marker of response. We found a high rate of
Fig 1. Methylation assay of non-methylated and methylated CLL
patients. The lower band corresponds to p53 exon 6 (used as internal
control) and the upper band corresponds to the promoter region that
encompasses the restriction sites analysed. Lane 1: PCR for patient
sample without restriction enzyme added to the digestion reaction;
lanes 2–5: PCR for patient sample after digestion with HpaII (lane 2),
MspI (lane 3), EcoRII (lane 4), BstNI (lane 5). Lane 6: undigested
control for the normal sample (no restriction enzyme added to the
digestion reaction); lanes 7–10: PCR for the normal sample after
digestion with HpaII (lane 7), MspI (lane 8), EcoRII (lane 9), BstNI
(lane 10). Lanes M, molecular marker.
Fig 2. Mutation analysis of p53 exon 5. (Top) Mutation analysis of
four patients with CLL. Lanes 1, 3, 4: cases 3, 25 and 30, respectively,
showing a normal pattern; Lane 2: case 23 showing an aberrant pattern,
wt: normal DNA; mut: Mutant control, M: 1 Kb plus molecular weight
marker. (B) Sequence analysis of case 23 confirming the mutation in
this patient (g179C>G, wild type amino acid His, mutant amino acid
Asp).
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response even in patients with p53 aberrations, in contrast to
previously published works that associated the presence of p53
aberrations with non-response to fludarabine (el Rouby et al,
1993; Dohner et al, 1995). 40% of our patients treated (17/42)
presented p53 aberrations and 11 responded to treatment.
Interestingly, we found 18Æ5% of the patients had methylation
in at least one of the four regions studied. All these patients
needed to be treated, suggesting the poor prognosis associated
with this epigenetic aberration, although this did not reach
statistical significance, probably because of the small number
of patients. Deletions in p53 and methylation of the p53
promoter seem to be independent factors (P ¼ 0Æ5516).
Although the role of p53 in the pathogenesis of CLL is still
unclear, the study of the integrity and functionality of the p53
pathway is acquiring importance. Hypermethylation could
explain disruption of the p53 pathway through an alternative
mechanism to deletion and mutation. The reduction of p53
gene dosage without inactivating mutation has been shown to
be sufficient to promote tumorigenesis in p53 heterozygous
mice (Venkatachalam et al, 1998), therefore, this could suggest
that a reduction in the expression of p53 caused by methy-
lation of the promoter region might be sufficient to promote
the selection and expansion of pretumoural cells. The contri-
bution of p53 to the nucleoside-induced killing of CLL cells is
controversial. Our study would support the hypothesis of
Pettitt et al (1999a,b), which suggests that the poor clinical
response to nucleoside therapy observed in CLL patients with
Table III. Univariate analysis of variables rela-
ted to response to treatment with fludarabine in








<60 4 4 0Æ0090* )41Æ18 ()70Æ23; )9Æ38)
>60 31 3
Sex




Yes 5 4 0Æ0153* 35Æ35 (5Æ97; 64Æ85)
No 30 3
del(11q)
Yes 9 3 0Æ2755 14Æ37 ()9Æ33; 44Æ67)
No 26 4
Trisomy 12
Yes 6 0 0Æ4121 )19Æ44 ()35Æ03; 20Æ77)
No 29 7
del(13q)
Yes 8 1 0Æ8006 )7Æ07 ()25Æ67; 26Æ70)
No 27 6
Methylation TP53
Yes 7 3 0Æ2482 17Æ50 ()7Æ23; 48Æ74)
No 28 4
Methylation TP53 and no del(17p)
Yes 1 3 0Æ018* 57Æ76 (9Æ61,80Æ36)
No 24 5
TP53 aberrations
Yes 11 6 0Æ0065* 31Æ29 (7Æ52; 54Æ93)
No 24 1
IGVH status
Mutated 14 1 0Æ4561 )9Æ12 ()31Æ58; 16Æ20)
Non-mutated 16 3







Sex (M/F) 8/10 16/9
Age (years) 68Æ53 68Æ72
FISH
Normal 3 4 0Æ8401
del(17)(p13) 5 5 0Æ5989
del(11)(q22) 3 13 0Æ0194
Trisomy 12 5 5 0Æ5989
del(13)(q14) 11 16 0Æ6475
Methylation (yes) 4 5 0Æ8800
p53 and Response to Fludarabine in Advanced Stages CLL
ª 2005 Blackwell Publishing Ltd, British Journal of Haematology, 129, 53–59 57
p53 abnormalities is unlikely to be due to nucleoside resistance
at the time of diagnosis. The genomic instability associated
with the p53 dysfunction would facilitate the evolution during
the course of the disease of CLL cell clones, which become
resistant to nucleoside therapy for reasons not directly
connected with p53 (Pettitt et al, 1999a,b).
There are many questions regarding the pathogenesis of CLL
that remain unanswered. Considering the heterogeneous
evolution of CLL, the challenge is to continue to accurately
identify the therapeutic strategy most likely to benefit
individual patients. Cancer cells are exceptionally sensitive to
reactivation of p53 function and therefore, treatments that
achieve this could be very effective (Lane, 2004). In conclusion,
the presence of p53 aberrations, including methylation of its
promoter, was the only genetic factor predicting non-response
to fludarabine as first-line therapy, confirming the importance
of this event in CLL. However, a high percentage of patients
with p53 aberrations responded to fludarabine, suggesting that
the poor clinical response to purine analogue therapy observed
in CLL patients with p53 abnormalities is unlikely to be
because of resistance to this therapy at diagnosis. For
individual risk-adapted therapy, global mechanism of p53
inactivation should be evaluated in a larger group of patients.
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